SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Home
/
update
/
details

APIS Announces Partnership with Shiva Scientific to Distribute ESR1 Mutations Kit in India

NextEdge Admin

02 Aug 2024

2 min 7 sec

APIS announced a strategic partnership with Shiva Scientific, naming them the exclusive distributor of the APIS ESR1 Mutations Kit in India. This collaboration underscores APIS's commitment to enhancing disease prediction and prevention on a global scale.

The APIS ESR1 Mutations Kit is a state-of-the-art qPCR assay designed for the sensitive and accurate detection of mutations in the oestrogen receptor gene. This qualitative test identifies eleven ESR1 mutations across exons 5, 7, and 8, including E380Q, S463P, P535H, L536R, L536Q, L536H, L536P, Y537C, Y537S, Y537N, and D538G. Utilizing mutation-specific probes and PCR clamp and blocker technology, the kit ensures specific amplification of mutant sequences even in the presence of a high wild-type background.

Key benefits of the APIS ESR1 Mutations Kit include:

- Wide target coverage: Detects 11 different ESR1 mutations.
- High specificity: Clamp and blocking technology prevents wild-type detection.
- High sensitivity: Detects mutations at ≤ 1% MAF (Mutant Allele Frequency).
- User-friendly: Simple protocol with optimized reagents for precise detection in human DNA.

Suitable for both centralized and decentralized settings, the APIS ESR1 Mutations Kit offers a reliable testing solution without the need for additional specialized equipment such as NGS, making it accessible and practical for various facilities. This partnership marks a significant step in advancing molecular pathology workflows in India.